BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted nanoparticle therapeutics, headquartered in Cambridge, Massachusetts.
- Company typePrivate
- Founded2006
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What BIND Therapeutics does
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics intended to concentrate drug activity at disease sites while limiting exposure to healthy tissue. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company built its operating model around proprietary nanoparticle engineering — encapsulating therapeutic payloads within targeted nanoparticles designed to bind to specific cells or tissues. The platform positioned BIND as a programmable delivery system applicable across multiple therapeutic payloads and disease areas.\n\nThe company served the pharmaceutical R&D market rather than end patients directly. As a clinical-stage entity, BIND generated no commercial product revenue. Its go-to-market and revenue mechanics depended on advancing Accurins candidates through preclinical and clinical development, then either licensing or co-developing with larger pharmaceutical partners for milestone and royalty payments, or being acquired outright. Capitalization has been driven by venture financing — approximately $91.85 million disclosed across seven rounds from 2007 through 2015 — led by syndicates including ARCH Venture Partners, Flagship Pioneering, Polaris Partners, ND Capital, Endeavour Vision, and RUSNANO. The company also accessed public markets via a NASDAQ listing under ticker BIND, which is now delisted; the input does not specify the listing or delisting dates.\n\nConfirmed leadership on the public record is limited to Daniel Lynch as Chairman of the Board and Jim Wright as Chief Scientific Officer. Broader operating team composition, pipeline progression, and post-2015 operating activity are not disclosed in the available input, indicating either limited post-delisting public footprint or material data gaps.
BIND Therapeutics firmographics
Firmographics- Name
- BIND Therapeutics
- Website
- https://bindtherapeutics.com
- Company type
- Private
- Founded year
- 2006
- Headcount range
- 51–100 employees
- Short description
- BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted nanoparticle therapeutics, headquartered in Cambridge, Massachusetts.
- Ownership category
- akta.pro rank
BIND Therapeutics industry classification
Industry- Product category
- Targeted Nanomedicine Therapeutics
- NAICS
- Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
- akta.pro secondary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where BIND Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
BIND Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
BIND Therapeutics product offering
Product offeringCore offering
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a proprietary class of highly selective, targeted polymeric nanoparticle therapeutics. These therapeutics are engineered to deliver drug payloads preferentially to diseased cells while minimizing exposure to healthy tissue, addressing limitations of conventional drug delivery in oncology and other disease areas.
Differentiator
Problem solved
Functional benefit
Products and services
- Accurins Platform A proprietary class of highly selective, targeted polymeric nanoparticle therapeutics engineered to deliver drug payloads directly to diseased cells while sparing healthy tissue. Designed for pharmaceutical partners developing treatments in oncology and other disease areas.
Companies that use BIND Therapeutics
Customer profileIdeal customer profiles1 record
BIND Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BIND Therapeutics partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
BIND Therapeutics competitors and assessment
Company assessmentDirect peers
- Camurus: Commercial-stage Swedish company commercializing nanoscale drug delivery using its proprietary FluidCrystal® technology. Directly comparable in developing engineered nanoscale delivery solutions for poorly soluble and targeted therapeutics.
- Arrowhead Pharmaceuticals: Clinical-stage company developing targeted RNAi therapeutics via its TRIM™ and other proprietary delivery platforms. Closely comparable in applying targeted nanoparticle delivery across multiple therapeutic programs.
- Selecta Biosciences: Clinical-stage company developing synthetic nanoparticle therapeutics for immunomodulation and targeted delivery. Directly comparable to BIND as a nanoparticle-platform biotech with similar payload-flexibility strategy.
- NanoCarrier: Japanese clinical-stage biotech developing polymeric micelle nanoparticle therapeutics (e.g., NC-6004, NC-6300). Closely comparable to BIND's Accurin approach of encapsulating payloads in polymeric nanoparticles for targeted delivery.
- Arcturus Therapeutics: Develops lipid nanoparticle-enabled RNA therapeutics. Comparable to BIND as a clinical-stage platform company whose core value rests on engineered nanoparticle delivery technology applied to multiple payload classes.
Broad incumbents
- Alnylam Pharmaceuticals: Commercial-stage leader in RNAi therapeutics using lipid nanoparticle and GalNAc conjugate delivery systems. A broader-incumbent comparable: a targeted-therapeutics platform company with validated clinical and commercial nanoparticle delivery at much larger scale.
- Moderna: Commercial-stage mRNA therapeutics company with industry-leading lipid nanoparticle delivery platform. Comparable as a nanoparticle-based therapeutics platform company, though far larger in scale and capital.
Emerging players
- Acuitas Therapeutics: Specializes in lipid nanoparticle delivery technology for nucleic acid therapeutics and has major partnerships with large pharma. Comparable as a technology-provider-model nanoparticle delivery company, though more focused on nucleic acid payloads.
- Cristal Therapeutics: European clinical-stage biotech developing polymeric nanoparticle therapeutics (CriPec® platform). Highly comparable to BIND's polymeric nanoparticle delivery technology and clinical-stage positioning.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
BIND Therapeutics social profiles
Digital presenceBIND Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BIND Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
BIND Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BIND Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BIND Therapeutics
What does BIND Therapeutics do?
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a proprietary class of highly selective, targeted polymeric nanoparticle therapeutics. These therapeutics are engineered to deliver drug payloads preferentially to diseased cells while minimizing exposure to healthy tissue, addressing limitations of conventional drug delivery in oncology and other disease areas.
When was BIND Therapeutics founded?
BIND Therapeutics was founded in 2006. It employs 51 to 100 people.
Where is BIND Therapeutics based?
BIND Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are BIND Therapeutics's main competitors?
Direct peers on record are Camurus, Arrowhead Pharmaceuticals, Selecta Biosciences, NanoCarrier and Arcturus Therapeutics. Broad incumbents are Alnylam Pharmaceuticals and Moderna. Emerging players are Acuitas Therapeutics and Cristal Therapeutics.
Does BIND Therapeutics have an API?
No public API is recorded for BIND Therapeutics.
What industry is BIND Therapeutics in?
BIND Therapeutics's product category is Targeted Nanomedicine Therapeutics. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 541713 and its SIC code is 2834.